ARTES Biotechnology GmbH and NL Biotechnologies LLC join in a strategic collaboration and co-marketing alliance

06-Sep-2011 - Germany

ARTES Biotechnology and NL Biotechnologies started a strategic collaboration. With signing this collaboration agreement the two companies combine their know-how and technologies in yeast expression, process and vaccine development. The direct and noticeable aim is the marketing of efficient and cost effective vaccines and diagnostics proteins.

The first product that is available right from the start is a Hansenula polymorpha derived Hepatitis E vaccine. Proof-of-principle and animal studies (mice and macaques) have been done and shown very good result and high immune answers.

“The Hepatitis E transmission is a person-to-person one, normally triggered to the fecal-oral route. Infections occur because of consumption of contaminated water and ingestion of raw or uncooked food – therefore it is a disease most common in developing countries,“ Vitaly Granovskiy, managing director of NL Biotechnologies carried out.
And Dr. Michael Piontek, managing director of ARTES added, ”With the Hepatitis E process we have another reliable and cost-efficient VLP-based production process in our portfolio. Like for HepB and avian flu, the manufacturing costs for this vaccine are low because of the effective technology behind. In our mind, it should be an interesting process particular for developing countries. “

The partners are now looking for companies to out-license the process.

https://www.bionity.com/en/news/134217/artes-biotechnology-gmbh-and-nl-biotechnologies-llc-join-in-a-strategic-collaboration-and-co-marketing-alliance.html